Atrium Therapeutics, Inc. SEC filings RNA
Atrium Therapeutics, Inc. has 55 filings in SEC EDGAR's recent list, going back to Dec 10, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| 4 | Insider transaction | Sep 22, 2026 | Sep 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 27, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 27, 2026 | — |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 8, 2026 | — |
| 4 | Insider transaction | Mar 2, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 27, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2093101
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.